Minimal residual disease evaluation in acute myeloid leukaemia

This publication has 24 references indexed in Scilit:

• The significance of minimal residual disease in patients with t(15;17)
  Best Practice & Research Clinical Haematology, 2002
• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
  Blood, 2001
• Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
  Blood, 2000
• Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
  Leukemia, 2000
• Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
  Blood, 1999
• Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance
  British Journal of Haematology, 1999
• Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial
  Blood, 1999
• The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
  Blood, 1998
• Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial
  Blood, 1998
• Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients
  Blood, 1997